Foley Partner David Rosen was quoted in an article that appeared in FDA Week on June 24, 2010 titled “OIG, Stakeholders Urge FDA To Clamp Down On Foreign Clinical Trials.” Rosen discusses criticisms directed towards the Food and Drug Administration (FDA) by lawmakers and drug safety advocates for what they view as lackluster oversight of clinical trials conducted abroad. He states that data collected during pivotal trials is likely to come under scrutiny by the FDA, adding that the majority of companies are working hard to ensure that data generated outside the U.S. is of very high quality.
People
Related News
August 13, 2025
In the News
Leigh Riley on Elevating Partner Development with Foley's PEAK Program – 'We can't stop learning'
Foley & Lardner LLP partner Leigh Riley appeared on the Big Law Life podcast to share how Foley is redefining professional development to meet the needs of the firm's partners and the demands of modern legal practice.
August 8, 2025
In the News
Gregory Husisian and David Simon Uncover the High Stakes of Tariff Evasion
Foley & Lardner LLP partners Gregory Husisian and David Simon are featured for their insights on how the U.S. government is cracking down on tariff evaders in the Newsweek article, "America Is Making Billions From Catching 'Tariff Cheaters.'"
August 7, 2025
In the News
Kyle Faget Weighs in on Trump Pharma Tariffs
Foley & Lardner LLP partner Kyle Faget assessed the Trump administration's implementation of import tariffs on the pharmaceutical industry in the Pharma Life Sciences article, "Trump's pharma import tariffs threaten drug pricing, generics."